Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Executive Management
Corporate Directory
Products
DAYBUE™ (trofinetide)
Pipeline
Pipeline
Trofinetide
Rett Syndrome
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Prader-Willi Syndrome
Science
Science Behind Neuren's Products
Trofinetide Published Studies & Presentations
Rett Syndrome
NNZ-2591Published Studies & Presentations
Phelan-McDermid Syndrome
Pitt Hopkins Syndrome
Angelman Syndrome
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2025
2024
2023
2022
2021
2020
2019
2018
Older
Sep 13, 2021
Proposed issue of securities - NEU
Sep 13, 2021
Placement to accelerate NNZ-2591 across 4 indications
Sep 10, 2021
Notification of investor presentation, 9.00 AEST 13 Sept 21
Sep 09, 2021
Trading Halt
Sep 03, 2021
FDA grants Orphan Drug designation for Prader-Willi syndrome
Sep 01, 2021
Angelman IND and Ethics applications submitted for NNZ-2591
Sep 01, 2021
Trofinetide Rett syndrome clinical trial in girls aged 2-5
Aug 30, 2021
R&D Tax Incentive Advance Overseas Finding Approval
Aug 25, 2021
Half-year shareholder update
Aug 25, 2021
Half Yearly Report and Accounts
Previous
1
2
3
4
5
6
Next